EU Acne Guideline

57 Pages·2017·0.83 MB·English

This is an Open Access document downloaded from ORCA, Cardiff University's
institutional repository: https://orca.cardiff.ac.uk/id/eprint/101673/
This is the author’s version of a work that was submitted to / accepted for
publication.
Citation for final published version:
Nast, A., Dreno, B., Bettoli, V., Bukvic Mokos, Z., Degitz, K., Dressler, C.,
Finlay, Andrew Yule ORCID: https://orcid.org/0000-0003-2143-1646,
Haedersdal, M., Lambert, J., Layton, A., Lomholt, H. B., Lopez-Estebaranz, J.
L., Ochsendorf, F., Oprica, C., Rosumeck, S., Simonart, T., Werner, R. N. and
Gollnick, H. 2016. European evidence-based (S3) guideline for the treatment
of acne - update 2016 - short version. Journal of the European Academy of
Dermatology and Venereology 30 (8) , pp. 1261-1268. 10.1111/jdv.13776 file
Publishers page: http://dx.doi.org/10.1111/jdv.13776
<http://dx.doi.org/10.1111/jdv.13776>
Please note:
Changes made as a result of publishing processes such as copy-editing,
formatting and page numbers may not be reflected in this version. For the
definitive version of this publication, please refer to the published source. You
are advised to consult the publisher’s version if you wish to cite this paper.
This version is being made available in accordance with publisher policies.
See
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights
for publications made available in ORCA are retained by the copyright
holders.
European Evidence-based (S3)
Guideline for the Treatment of Acne
(ICD L70.0)
Update 2016

Expiry date: 31.12.2020

A. Nast1, B. Dréno2, V. Bettoli3, Z. Bukvic Mokos4, K. Degitz5, C. Dressler1, A.Y. Finlay6, M.
Haedersdal7, J. Lambert8, A. Layton9, H.B. Lomholt10, J.L. López-Estebaranz11, F.
Ochsendorf12, C. Oprica13, S. Rosumeck1, T. Simonart14, R.N. Werner1, H. Gollnick15

1 Division of Evidence-Based Medicine, Klinik für Dermatologie, Charité - Formatted: German (Germany)
Universitätsmedizin Berlin, Berlin, Germany
2 Department of Dermatocancerolgy, Nantes University Hospital, Hôtel-Dieu, Nantes,
France
3 Department of Clinical and Experimental Medicine, Section of Dermatology, University of
Ferrara, Ferrara, Italy
4 University Hospital Center Zagreb, Zagreb, Croatia
5 Dermatologist in Private Practice, Munich, Germany
6 Department of Dermatology and Wound Healing, Cardiff University School of Medicine,
Cardiff, UK
7 Department of Dermatology, Bispebjerg Hospital, University of Copenhagen,
Copenhagen, Denmark
8 University Hospital of Antwerp, University of Antwerp, Belgium
9 Department of Dermatology, Harrogate and District Foundation Trust, Harrogate, North
Yorkshire, UK
10 Aarhus Universitet, Aarhus, Denmark
11 Dermatology Department, Alcorcon University Hospital Foundation, Alcorcón, Madrid,
Spain
12 Department of Dermatology and Venereology, University of Frankfurt, Frankfurt,
Germany
13 Department of Medicine, Division of Dermatology and Venereology, Karolinska Institutet,
Karolinska University Hospital, Stockholm, Sweden
14 Private practice, Anderlecht, Belgium
15 Department of Dermatology and Venereology, University of Magdeburg, Magdeburg,
Germany

1
Table of contents
1 Introduction ..............................................................................................................................5
1.1 Notes on use of guideline ....................................................................................................5
1.2 Objectives of the guideline...................................................................................................5
1.3 Target population ................................................................................................................6
1.4 Pharmacoeconomic considerations .....................................................................................6
1.5 Considerations with respect to vehicle for topical treatments ................................................6
1.6 Considerations with respect to body area ............................................................................7 Deleted: 6
1.7 Clinical features and variants ...............................................................................................7
1.7.1 Comedonal acne ...........................................................................................................7
1.7.2 Papulopustular acne .....................................................................................................7
1.7.3 Nodular/ conglobate acne .............................................................................................7
1.7.4 Other acne variants .......................................................................................................8
2 Assessment, comparability of treatment outcomes ...............................................................9
2.1 Acne grading .......................................................................................................................9
2.1.1 Acne grading systems ...................................................................................................9
2.2 Prognostic factors that should influence treatment choice .................................................. 13
2.2.1 Prognostic factors of disease severity.......................................................................... 13
2.2.2 The influence of the assessment of scarring/ potential for scarring on disease
management ............................................................................................................... 13
3 Epidemiology and pathophysiology ...................................................................................... 15
3.1 Epidemiology .................................................................................................................... 15
3.2 Pathophysiology ................................................................................................................ 15
4 Methods - Assessment of evidence ....................................................................................... 17
4.1 Grade of evidence (quality of individual trial) ...................................................................... 17
4.2 Level of evidence (quality of body of evidence to answer a specific question) .................... 17
4.3 Consensus process ........................................................................................................... 18
5 Induction therapy ................................................................................................................... 19
5.1 Treatment of comedonal acne ........................................................................................... 20
5.1.1 Recommendations for comedonal acne ....................................................................... 20
5.1.2 Reasoning .................................................................................................................. 20
5.2 Treatment of papulopustular acne ..................................................................................... 23
5.2.1 Recommendations for mild to moderate papulopustular acne 1 .................................... 23
5.2.2 Recommendations for severe papulopustular/ moderate nodular acne 1 ...................... 24
5.2.3 Reasoning .................................................................................................................. 25
5.3 Treatment of severe nodular/ conglobate acne .................................................................. 32
5.3.1 Recommendations for severe nodular/ conglobate acne 1 ........................................... 32
5.3.2 Reasoning .................................................................................................................. 33
5.4 General considerations ...................................................................................................... 35 Deleted: 34
5.4.1 Choice of type of topical retinoid .................................................................................. 35
5.4.2 Choice of type of systemic antibiotic ............................................................................ 35 Deleted: 34
5.4.3 Considerations on isotretinoin and dosage .................................................................. 36
5.4.4 Oral isotretinoin considerations with respect to EMA directive ...................................... 37 Deleted: 36
5.4.5 Consideration on isotretinoin and the risk of depression .............................................. 38
5.4.6 Risk of antibiotic resistance ......................................................................................... 39
2
6 Maintenance therapy .............................................................................................................. 42 Deleted: 41
6.1 Recommendations ............................................................................................................ 42 Deleted: 41
6.2 Background ....................................................................................................................... 43 Deleted: 42
6.3 Reasoning ......................................................................................................................... 46 Deleted: 45
7 References .............................................................................................................................. 48 Deleted: 47
8 Supporting information .......................................................................................................... 56 Deleted: 55
3
List of abbreviations
ADR adverse drug reaction
BPO benzoyl peroxide
CY cyst
IL inflammatory lesions
IPL intense pulsed light
LE level of evidence
ne no evidence
NIL non-inflammatory lesions
NO nodule
PDT photodynamic therapy
sys. systemic
TL total lesion
top. topical
UV ultraviolet
vs. versus
4
1 Introduction
Nast
1.1 Notes on use of guideline
An evidence-based guideline has been defined as ‘a systematically developed
statement that assists clinicians and patients in making decisions about appropriate
treatment for a specific condition’ [1]. A guideline will never encompass therapy
specifications for all medical decision-making situations. Deviation from the
recommendations may, therefore, be justified in specific situations.
This is not a textbook on acne, nor a complete, all-inclusive reference on all aspects
important to the treatment of acne. The presentation on safety in particular is limited
to the information available in the included clinical trials and does not represent all
the available and necessary information for the treatment of patients. Additional
consultation of specific sources of information on the particular intervention
prescribed (e. g. product information sheet) is necessary. Furthermore, all patients
should be informed about the specific risks associated with any given topical and/ or
systemic therapy.
Readers must carefully check the information in this guideline and determine whether
the recommendations contained therein (e. g. regarding dose, dosing regimens,
contraindications, or drug interactions) are complete, correct, and up-to-date. The
authors and publishers can take no responsibility for dosage or treatment decisions.
1.2 Objectives of the guideline
Improvement in the care of acne patients
The idea behind this guideline is that recommendations based on a systematic
review of the literature and a structured consensus process will improve the quality of
acne therapy in general. Personal experiences and traditional therapy concepts
should be critically evaluated and replaced, if applicable, with the consented
therapeutic recommendations. In particular, a correct choice of therapy should be
facilitated by presenting the suitable therapy options in a therapy algorithm, taking
into account the type of acne and the severity of the disease.
Reduction of serious conditions and scarring
As a result of the detailed description of systemic therapies for patients with severe
acne, reservations about these interventions should be overcome to ensure that
patients receive the optimal therapy. With the timely introduction of sufficient
therapies, the development of serious post-acne conditions, severe scarring and
adverse psychosocial impact should be reduced.
Promotion of adherence
Good therapeutic adherence is key to treatment success. Adherence is facilitated by
knowledge of the product being used, for example treatment duration, the expected
onset of effect, the sequence of the healing process, the maximal achievable
average effect, expected adverse events, and the benefit to quality of life.
5
Reduction of antibiotic resistance
The use of topical and systemic antibiotics should be optimized by using appropriate
combinations for a predefined duration, in order to reduce the development of
antibiotic resistance.
1.3 Target population
Health care professionals
This guideline has been developed to help health care professionals provide optimal
therapy to patients with mild, moderate or severe acne. The primary target groups
are dermatologists and other professionals involved in the treatment of acne, such as
paediatricians and general practitioners. The target group may vary with respect to
national differences in the distribution of services provided by specialists or general
practitioners.
Patients
The recommendations of the guideline refer to patients who suffer from acne. These
are mainly adolescents treated in outpatient clinics. The appropriate therapy option is
presented according to the type of acne that is present. The primary focus is the
induction therapy of facial acne, recommendations also encompass patients with
more widespread acne affecting the trunk (see Chapter 1.6). Non-primary target
groups are patients with special forms of acne, such as, occupational acne,
chloracne, acne aestivalis, acne neonatorum and acne inverse (hidradenitis
suppurativa).
1.4 Pharmacoeconomic considerations
European guidelines are intended for adaptation to national conditions. It is beyond
the scope of this guideline to take into consideration the specific costs and
reimbursement situations in every European country. Differences in prices,
reimbursement systems, willingness and ability to pay for medication among patients
and the availability of generics are too large. Therefore, pharmacoeconomic
considerations will have to be taken into account when guidelines are developed at
national and local levels.
The personal financial and health insurance situation of a patient may necessitate
amendments to the prioritisation of treatment recommendations. However, if financial
resources allow, the suggested ranking in the therapeutic algorithm should be
pursued.
1.5 Considerations with respect to vehicle for topical treatments
The skin type, the sex and stage of disease has to be taken into consideration when
choosing the vehicle for topical treatments. The efficacy and safety/ tolerability of
topical treatments are influenced by the choice of vehicle.
6
1.6 Considerations regarding area of involvement Deleted: with respect to body area
The face is the primary region of interest for the treatment of acne. Appearance,
scarring, quality of life and social stigmatization are important considerations when
dealing with facial dermatological diseases.
The recommendations of this guideline apply primarily to the treatment of facial acne.
More widespread involvement will certainly favour earlier use of a systemic treatment
due to the efficacy and practicability of such treatments.
1.7 Clinical features and variants
Layton/ Finlay
Acne (synonym “acne vulgaris”) is a polymorphic, inflammatory skin disease nearly
always affecting the face (99 % of cases). It also commonly affects the back (60 %)
and chest (15 %) [2]. Seborrhoea is a frequent feature [3].
The clinical picture embraces a spectrum of signs, ranging from mild comedonal
acne, with or without sparse inflammatory lesions (IL), to acne conglobate or
aggressive fulminate disease with deep-seated inflammation, nodules and in some
cases associated systemic symptoms.
1.7.1 Comedonal acne
Clinically non-inflamed lesions develop from the subclinical microcomedo which is
evident on histological examination early in acne development [2]. Non-inflamed
lesions encompass both open (blackheads) and closed comedones (whiteheads).
Comedones frequently have a mid-facial distribution in childhood and, when evident
early in the course of the disease, this pattern is indicative of poor prognosis [4].
Closed comedones are often inconspicuous with no visible follicular opening.
1.7.2 Papulopustular acne
Most patients have a mixture of non-inflammatory (NIL) and inflammatory lesions [5].
Inflammatory lesions arise from the microcomedo or from non-inflammatory clinically
apparent lesions and may be either superficial or deep [6]. Superficial inflammatory
lesions include papules and pustules (5 mm or less in diameter). These may evolve
into nodules in more severe disease. Inflammatory macules represent regressing
lesions that may persist for many weeks and contribute markedly to the general
inflammatory appearance [5].
1.7.3 Nodular/ conglobate acne
Nodules are defined as firm, inflamed lesions >10 mm diameter, painful by palpation.
[7]. They may extend deeply and over large areas, frequently resulting in painful
lesions, exudative sinus tracts and tissue destruction. Conglobate acne is a rare but
severe form of acne found most commonly in adult males with few or no systemic
symptoms. Lesions usually occur on the trunk and upper limbs and frequently extend
to the buttocks. In contrast to ordinary acne, facial lesions are less common. The
condition often presents in the second to third decade of life and may persist into the
7
sixth decade. Conglobate acne is characterized by multiple grouped comedones
amidst inflammatory papules, tender, suppurative nodules which commonly coalesce
to form sinus tracts. Extensive and disfiguring scarring is frequently a feature.
1.7.4 Other acne variants
There are several severe and unusual variants or complications of acne as well as
other similar diseases. These include acne fulminans, gram-negative folliculitis,
rosacea fulminans, vasculitis, mechanical acne, oil/ tar acne, chloracne, acne in
neonates and infants and late onset, persistent acne, sometimes associated with
genetic or iatrogenic endocrinopathies. The current guideline do not lend themselves
to comprehensive management of all of these variants.
8
2 Assessment, comparability of treatment outcomes
Finlay/ Layton
2.1 Acne grading
Acne can be largely assessed from two perspectives: objective disease activity
(based on measurement of visible signs) and quality of life impact. There are other
aspects of measurement, such as sebum excretion rate, colonisation by
Propionibacterium acnes (P. acnes), scarring development or economic impact.
Accurately assessing outcomes from therapy is notoriously difficult in acne [8]. Many
different approaches have been adopted but very few are validated. The inconsistent
application of a standard method for assessing acne severity makes it very difficult to
challenge interpretation of results from interventional studies. There are detailed
reviews and reflections on this subject by Lehmann et al. [9], Barratt et al. [10],
Witkowski et al. [11], Thiboutot et al. [12], Gollnick et al. [13] and Tan et al. [14].
Proper lighting, appropriate patient positioning and prior facial skin preparation
(gentle shaving for men, removal of make-up for women) are helpful in facilitating
accurate assessment. Palpation in addition to visual inspection may also help define
lesions more accurately.
Mechanisms to assess acne lesions using digital multimodal imaging are being
evaluated but have not yet been accepted or validated for use in clinical practice [15].
Patient reported outcomes are now also being considered as an important part of
overall assessment [16]. However, the most frequently used outcome measures to
assess acne involve grading or counting. These evaluations can be further divided
into: (i) an evaluation according to the predominant lesion type; (ii) evaluations of
separate individual lesions; (iii) overall or ‘global’ assessment. Lesion counts are
essential for clinical trials as they offer a reliability not evident in global assessment,
however counting remains impractical for use in the day-to-day clinic [17] and does
not accurately reflect overall severity [18]. In systematic reviews, global grading has
been used as an efficacy measure in up to 62% of acne trials [9, 10] and the USA
Food and Drug Administration (FDA) has mandated global grading as one of two
efficacy measures in which superiority must be demonstrated for approval of acne
therapies [18]. However, no one global system has been established as a standard:
some utilize quantitative measures e. g. lesion counts and numeric ranges and
others are based on qualitative descriptions.
2.1.1 Acne grading systems
2.1.1.1 Sign-based methods
Despite a range of methods being used to measure acne in the 1960’s and 1970’s, it
was the Leeds technique [5] that dominated acne measurement for the next two
decades. The Leeds technique included two methods; the grading technique and the
counting technique. The grading technique allocated patients a grade from 0 to 10,
with seven subgroups between 0 and 2. Photographic guides illustrating each grade
are given, but the importance of also palpating lesions is stressed. The experience
on which this system was based stemmed from the pre-isotretinoin era, and acne of
9